India, Sept. 10 -- Burning Rock Biotech Limited (BNR), a precision oncology company focused on next-generation sequencing (NGS) technology, reported financial results for the second quarter of 2026 and provided updates on its therapy selection and minimal residual disease (MRD) testing portfolio.
The company said several products have entered regulatory review pathways in China, supporting its efforts to expand its in-hospital business and drive long-term revenue growth.
Second Quarter Results
For the second quarter of 2026, Burning Rock reported revenue of RMB134.8 million, compared with RMB148.6 million in the prior-year quarter.
Revenue from the central laboratory business was RMB36.8 million, compared with RMB40.9 million in the pri...